Towa Pharmaceutical: Tanabe Pharma Factory to become subsidiary of Towa Pharmaceutical Quick Note

Research evidence excerpt

Towa Pharmaceutical: Tanabe Pharma Factory to become subsidiary of Towa Pharmaceutical Quick Note

Global Markets Research

6 July 2026Towa Pharmaceutical

4553.T 4553 JP / EQUITY: JAPAN PHARMACEUTICALS

Tanabe Pharma Factory to become subsidiary of Rating NeutralTowa Pharmaceutical

Target price JPY 4,400Quick Note

Closing price

3 July 2026 JPY 3,925Acquisition of Tanabe Pharma Factory stocks from Tanabe Pharma

On 3 July, Towa Pharmaceutical announced that it would acquire all shares of Tanabe (Note: Quick Note reports are not a

Pharma Factory, a pharmaceuticals manufacturing subsidiary of Tanabe Pharma, making vehicle for changes to ratings, target

Tanabe Pharma Factory a wholly-owned subsidiary. It also announced that it would prices, or earnings forecasts)

assume manufacturing and marketing approvals for 35 approved products covering 17

active pharmaceutical ingredients. A briefing session on this acquisition is scheduled for

3:30pm JST on 8 July.

Overview of share acquisition Research Analysts

The acquisition price has not been disclosed, and we expect negative goodwill. The Japan pharmaceuticals &

acquisition price for the transferred manufacturing and marketing approvals has also not healthcare

been disclosed and is expected to be recorded as intangible assets. The share transfer is Kyoichiro Shigemura - NSC

scheduled for end-November. Tanabe Pharma Factory's 26/3 results and financial position kyoichiro.shigemura@nomura.com

were as follows: sales at ¥15.78bn (down 15% y-y), operating profit totaling ¥1.14bn +81 3 6703 1118

(down 30%), total assets amounting to ¥39.9bn, and net assets at ¥31.7bn.

Positive first impression

We view this deal positively, as it should help the company build a stable supply